THE TGA has approved an update to the label of Bayer's Mirena, extending its contraceptive lifespan from five to eight years.
Prof Deborah Bateson, from the Faculty of Medicine and Health at the University of Sydney, highlighted the importance of this development.
She noted that the extension could boost the use of long-acting reversible contraceptives (LARC) in Australia, where their adoption rate is relatively low.
"Mirena with up to eight years is now the longest-acting hormonal contraceptive, and this extension may encourage more women to consider LARC," commented Bateson.
The update is based on the phase III Mirena extension trial, which confirmed the device's contraceptive efficacy of over 99% and its consistent safety profile through years six to eight.
"GPs, nurse practitioners and pharmacists across Australia, all have a role to play in facilitating informed contraceptive choice," Bateson added.
"We know that currently, only 7% of contraceptive consultations in general practice involve discussion of LARC.
"It is essential that women of reproductive age are informed of the pros and cons of the full range of contraceptive options; not just the various forms of the pill," she explained.
Prof Bateson called for expanded training and increased funding for LARC procedures to address these barriers.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jun 24
